Rosetta Capital is a specialist venture capital firm focused on the life science and medical technology sectors

 

We are a multinational team from the venture capital, pharmaceutical and biotechnology sectors. For almost 10 years, we have been working with entrepreneurs and young life science companies to help them achieve their ambitions. We have had the privilege to work with some great inventors and management teams, to witness the development of some amazing new product concepts and to participate in the evolution of some truly innovative companies. Currently, we manage funds comprising more than 25 underlying portfolio companies across Europe and North America.

 

Rosetta is focused on secondary transactions. We invest in portfolios of shareholdings to provide liquidity to other investors or corporations that, for strategic reasons, wish to divest some or all of their investment assets or to access additional capital and expertise to optimise portfolio company outcomes. From time to time, we also make direct primary venture investments. We seek to offer flexibility in transactional structure, to adapt our strategy to the investment climate and are always willing to explore good opportunities, even if outside our current focus.

 

Recently, we have ventured outside our core life science focus to invest in portfolios that include companies in the cleantech, information technology, software and electronics areas. We believe this helps to manage risk across investment sectors and cycles and is beneficial to our investors.

 

Rosetta is headquartered in the United Kingdom and has a presence in Canada, Germany and Switzerland.

 

Rosetta news

 

 

 

 

 

 

 

 


Recent portfolio company news